Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease

被引：274

作者：

Borghi, Claudio ^{[1
]}

Agabiti-Rosei, Enrico ^{[2
]}

Johnson, Richard J. ^{[3
]}

Kielstein, Jan T. ^{[4
]}

Lurbe, Empar ^{[5
,6
]}

Mancia, Giuseppe ^{[7
,8
]}

Redon, Josep ^{[6
,9
]}

Stack, Austin G. ^{[10
]}

Tsioufis, Konstantinos P. ^{[11
]}

机构：

[1] Univ Bologna, Dept Med & Surg Sci, Osped Malpighi, Via Albertoni 15, I-40138 Bologna, Italy

[2] Univ Brescia, Dept Clin & Expt Sci, Div Med, Viale Europa 11, I-25123 Brescia, Italy

[3] Univ Colorado, Dept Med, Anschutz Med Campus,12700 East 19th Ave, Aurora, CO USA

[4] Acad Teaching Hosp Braunschweig, Med Clin Nephrol Rheumatol & Blood Purificat 5, Salzdahlumer Str 90, D-38126 Braunschweig, Germany

[5] Gen Hosp Valencia, Pediat Dept, Av Menendez Pelayo 4, Valencia 46010, Spain

[6] CIBERObn, Av Menendez Pelayo 4, Valencia 46010, Spain

[7] Univ Milano Bicocca, Piazza AteneoNuovo 1, I-20126 Milan, Italy

[8] Policlin Monza, Monza, Italy

[9] INCLIVA Univ Valencia, Hosp Clin Valencia, Av Menendez Pelayo 4, Valencia 46010, Spain

[10] Univ Limerick, Univ Hosp Limerick, Grad Entry Med Sch, Dept Nephrol, Castletroy V94 T9PX, Co Limerick, Ireland

[11] Natl & Kapodistrian Univ Athens, Athens 15772, Greece

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2020年 / 80卷

基金：

美国国家卫生研究院;

关键词：

Allopurinol; Febuxostat; Hypertension; Hyperuricaemia; Metabolic syndrome; Type; 2; diabetes; SERUM URIC-ACID; XANTHINE-OXIDASE INHIBITION; URATE-LOWERING THERAPIES; HEART-FAILURE PATIENTS; BLOOD-PRESSURE; ASYMPTOMATIC HYPERURICEMIA; RISK-FACTORS; ENDOTHELIAL DYSFUNCTION; MYOCARDIAL-INFARCTION; MILD HYPERURICEMIA;

D O I：

10.1016/j.ejim.2020.07.006

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

During the last century, there has been an increasing prevalence of hyperuricaemia noted in many populations. While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hypertriglyceridaemia, obesity, atherosclerotic heart disease, metabolic syndrome, and type 2 diabetes. Here we review the connection between hyperuricaemia and cardiovascular, kidney and metabolic diseases. Contrary to the popular view that uric acid is an inert metabolite of purine metabolism, recent studies suggest serum uric acid may have a variety of pro-inflammatory, pro-oxidative and vasoconstrictive actions that may contribute to cardiometabolic diseases. Hyperuricaemia is a predictive factor for the development of hypertension, metabolic syndrome, type 2 diabetes, coronary artery disease, left ventricular hypertrophy, atrial fibrillation, myocardial infarction, stroke, heart failure and chronic kidney disease. Treatment with uric acid-lowering therapies has also been found to improve outcomes in patients with hypertension and kidney disease, in some but not all studies. In conclusion, uric acid is emerging as a potentially treatable risk factor for cardiometabolic diseases, and more clinical trials investigating the potential benefit of lowering serum uric acid are recommended in individuals with hyperuricaemia with and without deposition and concomitant hypertension, metabolic syndrome or chronic kidney disease.

引用

页码：1 / 11

页数：11

共 148 条

[1]

Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta-Analysis [J].